Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke

Journal of Infectious Diseases

Volumn 205, Issue 4, 2012, Pages 535-539

  Worm, S W ^a   Kamara, D A ^b   Reiss, P ^c   Fontas, E ^d   De Wit, S ^e   El Sadr, W ^f   D'Arminio Monforte, A ^g   Law, M ^h   Phillips, A ^b   Ryom, L ^a   Dabis, F ⁱ   Weber, R ^j   Sabin, C ^b   Lundgren, J D ^a,k  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^f Howard Hughes Medical Institute   (United States)

^g UNIVERSITY OF MILAN   (Italy)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ UNIVERSITÉ DE BORDEAUX   (France)

^j UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^k University Hospital of Copenhagen ^*  (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG CLASSIFICATION; DRUG EXPOSURE; DRUG USE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHEMORRHAGIC STROKE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SUDDEN DEATH; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; DEATH, SUDDEN; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; STROKE;

EID: 84856248004     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir788     Document Type: Article

References (14)

1. Singh M, Arora R, Jawad E. HIV protease inhibitors induced prolongation of the QT interval: electrophysiology and clinical implications. Am J Ther 2009; 17:e193-201.
2. Anson BD, Weaver JG, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet 2005; 365:682-6. (Pubitemid 40260891)
3. Ly T, Ruiz ME. Prolonged QT interval and torsades de pointes associated with atazanavir therapy. Clin Infect Dis 2007; 44:e67-8.
4. U.S. Food and Drug Administration. Labeling changes for Kaletra reflecting new QT/QTC interval and PR interval prolongation information. 2009. http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/ hivandaidsactivities/ucm155697.htm. Accessed 23 April 2010.
5. Soliman EZ, Lundgren JD, Mollie P, et al. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS 2011; 25:367-77.
6. Soliman EZ, Prineas RJ, Case D, et al. Ethnic distribution of electrocardiographic predictors of atrial fibrillation and its impact on understanding the ethnic distribution of ischemic stroke in the Atherosclerosis Risk in Communities Study (ARIC). Stroke 2009; 40:1204-11.
7. Cheng S, Keyes MJ, Larson MG, et al. Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA 2009; 301:2571-7.
8. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24:1537-48.
9. Worm SW, Sabin C, Reiss P, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. J Infect Dis 2010; 201: 318-30.
10. Ladich E, Virmani R, Burke A. Sudden cardiac death not relayed to coronary atherosclerosis. Toxicol Pathol 2006; 34:52-7. (Pubitemid 43323260)
11. Adabag SA, Luepker RV, Roger VL, Gersh BJ. Sudden cardiac death: epidemiology and risk factors. Nat Rev Cardiol 2010; 7:216-25.
12. Palussen ADC, Raes A, Jongbloed RJ, et al. HERG mutations predict short QT based on channel kinetics but causes long QT by heterotetrameric trafficking deficiency. Cardiovasc Res 2005; 67: 467-75. (Pubitemid 41019554)
13. Singh M, Arora R, Jawad E. HIV Protease inhibitors induced prolongation of the QT interval: electrophsyiology and clinical implications. Am J Ther 2010; 17:e193-201.
14. Kowalska JD, Friis-Moller N, Kirk O, et al. The Coding Causes of Death in HIV (CoDe) projectdinitial results and evaluation of methodology. The CoDe Working Group and the D:A:D Study Group. Epidemiology 2011; 22:516-23.